Eurofins Medinet, Chantilly, Virginia, USA.
Antimicrob Agents Chemother. 2013 Sep;57(9):4535-6. doi: 10.1128/AAC.00206-13. Epub 2013 Jun 17.
Clinical development of CEM-102 (fusidic acid) has recently begun in the United States for chronic oral treatment of prosthetic joint infections. To support this development, the in vitro activity of fusidic acid against important Staphylococcus aureus clones and resistance phenotypes was determined. Against 51 such isolates, the modal fusidic acid MIC was 0.12 μg/ml (range, 0.06 to 0.25 μg/ml for 49 isolates). This level of in vitro fusidic acid activity underscores the potential clinical utility of this compound in the United States.
CEM-102(夫西地酸)的临床开发最近已在美国开始,用于慢性口服治疗人工关节感染。为了支持这一发展,测定了夫西地酸对重要金黄色葡萄球菌克隆和耐药表型的体外活性。对 51 株此类分离株进行检测,夫西地酸的中值 MIC 为 0.12μg/ml(49 株分离株的范围为 0.06 至 0.25μg/ml)。这种体外夫西地酸活性水平突出了该化合物在美国的潜在临床应用。